162 related articles for article (PubMed ID: 26754826)
1. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.
Bernal T; Martínez-Camblor P; Sánchez-García J; Sanz G
Leukemia; 2016 Mar; 30(3):740-1. PubMed ID: 26754826
[No Abstract] [Full Text] [Related]
2. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.
Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Leukemia; 2015 Dec; 29(12):2449-51. PubMed ID: 26369829
[No Abstract] [Full Text] [Related]
3. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
[No Abstract] [Full Text] [Related]
4. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
Kantarjian HM
J Clin Oncol; 2002 May; 20(10):2415-6. PubMed ID: 12011118
[No Abstract] [Full Text] [Related]
5. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
Tomonaga M; Kamae I
Rinsho Ketsueki; 2012 Mar; 53(3):310-7. PubMed ID: 22499047
[TBL] [Abstract][Full Text] [Related]
6. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G
Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489
[No Abstract] [Full Text] [Related]
7. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
[TBL] [Abstract][Full Text] [Related]
8. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.
Liapis K; Papadopoulos V; Vrachiolias G; Galanopoulos AG; Papoutselis M; Papageorgiou SG; Diamantopoulos PT; Pappa V; Viniou NA; Kourakli A; Τsokanas D; Vassilakopoulos TP; Hatzimichael E; Bouronikou E; Ximeri M; Pontikoglou C; Megalakaki A; Zikos P; Panayiotidis P; Dimou M; Karakatsanis S; Papaioannou M; Vardi A; Kontopidou F; Harchalakis N; Adamopoulos I; Symeonidis A; Kotsianidis I
Blood Cancer J; 2021 Feb; 11(2):30. PubMed ID: 33574231
[No Abstract] [Full Text] [Related]
9. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.
Kamiya T; Nakazato T
Med Oncol; 2019 Jan; 36(3):25. PubMed ID: 30706221
[No Abstract] [Full Text] [Related]
10. Hematology: Azacitidine improves survival in myelodysplastic syndromes.
Rose MG
Nat Rev Clin Oncol; 2009 Sep; 6(9):502-3. PubMed ID: 19707240
[No Abstract] [Full Text] [Related]
11. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
12. Is there an association between 5-azacitidine and ototoxicity?
Malik A; Misbah S; Spaccavento C; Yudelman I
J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
[No Abstract] [Full Text] [Related]
13. Azacitine (vidaza) for myelodysplastic syndrome.
Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015
[TBL] [Abstract][Full Text] [Related]
14. Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?
Alessandrino EP; Della Porta MG; Pascutto C; Bacigalupo A; Rambaldi A
J Clin Oncol; 2013 Jul; 31(21):2761-2. PubMed ID: 23775971
[No Abstract] [Full Text] [Related]
15. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ
Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068
[No Abstract] [Full Text] [Related]
16. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
[No Abstract] [Full Text] [Related]
17. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
Takahashi Y; Kimura S; Okano M
Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323
[No Abstract] [Full Text] [Related]
18. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
Kumar A; List AF; Hozo I; Komrokji R; Djulbegovic B
Haematologica; 2010 Feb; 95(2):340-2; author reply 343-4. PubMed ID: 19850902
[No Abstract] [Full Text] [Related]
19. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.
Prébet T; Thepot S; Gore SD; Dreyfus F; Fenaux P; Vey N
Haematologica; 2013 Feb; 98(2):e18-9. PubMed ID: 22983576
[No Abstract] [Full Text] [Related]
20. Intravenous azacitidine for MDS.
Gore SD
Clin Adv Hematol Oncol; 2007 Mar; 5(3):234. PubMed ID: 17519884
[No Abstract] [Full Text] [Related]
[Next] [New Search]
